Natural products as sources of new drugs from 1981 to 2014

Lead- and drug-like compounds: the rule-of-five revolution

Lipinski, C. A. (2004) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2004.11.007 · Cited by 6,339 · see citing works

Natural products as sources of new drugs over the last 25 years

Newman, D. J., & Cragg, G. M. (2007) · Journal of Natural Products · doi:10.1021/np068054v · Cited by 5,517 · see citing works

On the size of the active site in proteases. I. Papain

Schechter, I., & Berger, A. (1967) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(67)80055-x · Cited by 5,203 · see citing works

Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study.

Liu, Y.-Y., Wang, Y., Walsh, T., Yi, L.-X., Zhang, R., Spencer, J., Doi, Y., Tian, G.-B., Dong, B.-L., Huang, X.-H., et al. (2016) · Lancet. Infectious Diseases (Print) · doi:10.1016/s1473-3099(15)00424-7 · Cited by 4,920 · see citing works

Natural products as sources of new drugs over the 30 years from 1981 to 2010

Newman, D. J., & Cragg, G. M. (2012) · Journal of Natural Products · doi:10.1021/np200906s · Cited by 4,687 · see citing works

Natural products as sources of new drugs over the period 1981–2002

Newman, D. J., Cragg, G. M., & Snader, K. M. (2003) · Journal of Natural Products · doi:10.1021/np030096l · Cited by 3,082 · see citing works

Natural products: A continuing source of novel drug leads

Cragg, G. M. L., & Newman, D. J. (2013) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2013.02.008 · Cited by 2,950 · see citing works

Martindale: the complete drug reference

(2005) · Choice Reviews Online · doi:10.5860/choice.42-6228 · Cited by 2,684 · see citing works

The re-emergence of natural products for drug discovery in the genomics era

Harvey, A. L., Edrada‐Ebel, R., & Quinn, R. J. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4510 · Cited by 2,601 · see citing works

Clinical development success rates for investigational drugs

Hay, M., Thomas, D. W., Craighead, J. L., Economides, C., & Rosenthal, J. (2014) · Nature Biotechnology · doi:10.1038/nbt.2786 · Cited by 2,536 · see citing works

Natural Products in Drug Discovery and Development

Cragg, G. M. L., Newman, D. J., & Snader, K. M. (1997) · Journal of Natural Products · doi:10.1021/np9604893 · Cited by 1,589 · see citing works

A Planning Strategy for Diversity‐Oriented Synthesis

Burke, M. D., & Schreiber, S. L. (2003) · Angewandte Chemie International Edition · doi:10.1002/anie.200300626 · Cited by 1,493 · see citing works

Impact of high-throughput screening in biomedical research

Macarron, R., Banks, M. N., Bojanic, D., Burns, D. J., Cirovic, D. A., Garyantes, T., Green, D. V. S., Hertzberg, R. P., Janzen, W. P., Paslay, J. W., et al. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3368 · Cited by 1,364 · see citing works

Chemistry: Chemical con artists foil drug discovery

Baell, J. B., & Walters, M. A. (2014) · Nature · doi:10.1038/513481a · Cited by 1,048 · see citing works

Oral Druggable Space beyond the Rule of 5: Insights from Drugs and Clinical Candidates

Doak, B. C., Over, B., Giordanetto, F., & Kihlberg, J. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.08.013 · Cited by 835 · see citing works

Haem-activated promiscuous targeting of artemisinin in Plasmodium falciparum

Wang, J., Zhang, C., Chia, W. N., Loh, C. S., Li, Z., Lee, Y. M., He, Y., Yuan, L., Lim, T. K., Liu, M., et al. (2015) · Nature Communications · doi:10.1038/ncomms10111 · Cited by 636 · see citing works

Natural product and natural product derived drugs in clinical trials

Butler, M. S., Robertson, A. A. B., & Cooper, M. A. (2014) · Natural Product Reports · doi:10.1039/c4np00064a · Cited by 604 · see citing works

An environmental bacterial taxon with a large and distinct metabolic repertoire

Wilson, M. C., Mori, T., Rückert, C., Uria, A. R., Helf, M. J., Takada, K., Gernert, C., Steffens, U. A. E., Heycke, N., Schmitt, S., et al. (2014) · Nature · doi:10.1038/nature12959 · Cited by 599 · see citing works

Discovery of small molecule cancer drugs: Successes, challenges and opportunities

Hoelder, S., Clarke, P. A., & Workman, P. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.02.004 · Cited by 582 · see citing works

Enhanced Activity of Monomethylauristatin F through Monoclonal Antibody Delivery: Effects of Linker Technology on Efficacy and Toxicity

Doronina, S. O., Mendelsohn, B. A., Bovee, T. D., Cerveny, C. G., Alley, S. C., Meyer, D. L., Oflazoglu, E., Toki, B. E., Sanderson, R. J., Zabinski, R. F., et al. (2005) · Bioconjugate Chemistry · doi:10.1021/bc0502917 · Cited by 515 · see citing works

Phenotypic screening in cancer drug discovery — past, present and future

Moffat, J. G., Rudolph, J., & Bailey, D. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4366 · Cited by 507 · see citing works

Structure-based design of aliskiren, a novel orally effective renin inhibitor

Wood, J. M., Maibaum, J., Rahuel, J., Grütter, M. G., Cohen, N.-C., Rasetti, V., Rüeger, H., Göschke, R., Stutz, S., Fuhrer, W., et al. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(03)01451-7 · Cited by 504 · see citing works

Modulators of Protein–Protein Interactions

Milroy, L.-G., Grossmann, T. N., Hennig, S., Brunsveld, L., & Ottmann, C. (2014) · Chemical Reviews · doi:10.1021/cr400698c · Cited by 497 · see citing works

Untitled work

Bergmann (1951) · doi:10.1021/jo01146a023 · Cited by 403 · see citing works

FDA Approval: Belinostat for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma

Lee, H.-Z., Kwitkowski, V. E., Valle, P. L. D., Ricci, M., Saber, H., Habtemariam, B. A., Bullock, J. M., Bloomquist, E. W., Shen, Y. L., Chen, X.-H., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3119 · Cited by 365 · see citing works

Ten things you should know about protein kinases: IUPHAR R eview 14

Fabbro, D., Cowan‐Jacob, S. W., & Möbitz, H. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13096 · Cited by 350 · see citing works

Diversity-oriented synthesis; a challenge for synthetic chemistsElectronic supplementary information (ESI) available: Excel file of all the FDA new molecular entities between the years 1998 and July 2003, and new drug approvals between the years 1990 and 2002. See http://www.rsc.org/suppdata/ob/b3/b310752n/

Spring, D. R. (2003) · Organic & Biomolecular Chemistry · doi:10.1039/b310752n · Cited by 347 · see citing works

Protein kinases as targets for anticancer agents: from inhibitors to useful drugs

Fabbro, D., Ruetz, S., Buchdunger, E., Cowan‐Jacob, S. W., Fendrich, G., Liebetanz, J., Mestan, J., O'Reilly, T., Traxler, P., Chaudhuri, B., et al. (2002) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00179-1 · Cited by 336 · see citing works

Structure-based drug design: the discovery of novel nonpeptide orally active inhibitors of human renin

Rahuel, J., Rasetti, V., Maibaum, J., Rüeger, H., Göschke, R., Cohen, N.-C., Stutz, S., Cumin, F., Fuhrer, W., Wood, J. M., et al. (2000) · Chemistry & Biology · doi:10.1016/s1074-5521(00)00134-4 · Cited by 321 · see citing works

Modern synthetic efforts toward biologically active terpenes

Maimone, T. J., & Baran, P. S. (2007) · Nature Chemical Biology · doi:10.1038/nchembio.2007.1 · Cited by 302 · see citing works

Natural-product-derived fragments for fragment-based ligand discovery

Over, B., Wetzel, S., Grütter, C., Nakai, Y., Renner, S., Rauh, D., & Waldmann, H. (2012) · Nature Chemistry · doi:10.1038/nchem.1506 · Cited by 301 · see citing works

A practical view of ‘druggability’

Keller, T. H., Pichota, A., & Yin, Z. Q. (2006) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2006.06.014 · Cited by 297 · see citing works

Solid-phase peptide synthesis: an overview focused on the preparation of biologically relevant peptides

Palomo, J. M. (2014) · RSC Advances · doi:10.1039/c4ra02458c · Cited by 275 · see citing works

THE ISOLATION OF A NEW THYMINE PENTOSIDE FROM SPONGES¹

Bergmann, W., & Feeney, R. J. (1950) · Journal of the American Chemical Society · doi:10.1021/ja01162a543 · Cited by 267 · see citing works

Recent advances in engineering nonribosomal peptide assembly lines

Winn, M., Fyans, J. K., Zhuo, Y., & Micklefield, J. (2015) · Natural Product Reports · doi:10.1039/c5np00099h · Cited by 266 · see citing works

Industrial natural product chemistry for drug discovery and development

Bauer, A., & Brönstrup, M. (2013) · Natural Product Reports · doi:10.1039/c3np70058e · Cited by 256 · see citing works

Conformational Analysis of the DFG-Out Kinase Motif and Biochemical Profiling of Structurally Validated Type II Inhibitors

Vijayan, R., He, P., Modi, V., Duong‐Ly, K. C., Ma, H., Peterson, J. R., Dunbrack, R. L., & Levy, R. M. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501603h · Cited by 255 · see citing works

Pharmaceuticals that contain polycyclic hydrocarbon scaffolds

Stockdale, T. P., & Williams, C. M. (2015) · Chemical Society Reviews · doi:10.1039/c4cs00477a · Cited by 254 · see citing works

Can Invalid Bioactives Undermine Natural Product-Based Drug Discovery?

Bisson, J., McAlpine, J. B., Friesen, J. B., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01009 · Cited by 249 · see citing works

Peptidomimetic design

Ripka, A. S., & Rich, D. H. (1998) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(98)80119-1 · Cited by 245 · see citing works

Critical review of the role of HTS in drug discovery

Macarrón, R. (2006) · Drug Discovery Today · doi:10.1016/j.drudis.2006.02.001 · Cited by 241 · see citing works

Use of Biomimetic Diversity-Oriented Synthesis to Discover Galanthamine-Like Molecules with Biological Properties beyond Those of the Natural Product

Pelish, H. E., Westwood, N. J., Feng, Y., et al. (2001) · Journal of the American Chemical Society · doi:10.1021/ja016093h · Cited by 208 · see citing works

Antiviral drug discovery: broad-spectrum drugs from nature

Martínez, J. P., Sasse, F., Brönstrup, M., Díez, J., & Meyerhans, A. (2014) · Natural Product Reports · doi:10.1039/c4np00085d · Cited by 199 · see citing works

CONTRIBUTIONS TO THE STUDY OF MARINE PRODUCTS. XXXIX. THE NUCLEOSIDES OF SPONGES. III.¹ SPONGOTHYMIDINE AND SPONGOURIDINE²

BERGMANN, W., & BURKE, D. C. (1955) · The Journal of Organic Chemistry · doi:10.1021/jo01128a007 · Cited by 194 · see citing works

From epoxomicin to carfilzomib: chemistry, biology, and medical outcomes

Kim, K. B., & Crews, C. M. (2013) · Natural Product Reports · doi:10.1039/c3np20126k · Cited by 175 · see citing works

Proteasome inhibitors

Teicher, B. A., & Tomaszewski, J. E. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.04.008 · Cited by 172 · see citing works

Current strategies for diversity-oriented synthesis

Dandapani, S., & Marcaurelle, L. A. (2010) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2010.03.018 · Cited by 171 · see citing works

Natural product synthesis in the age of scalability

Kuttruff, C. A., Eastgate, M. D., & Baran, P. S. (2013) · Natural Product Reports · doi:10.1039/c3np70090a · Cited by 171 · see citing works

Design and synthesis of analogues of natural products

Maier, M. E. (2015) · Organic & Biomolecular Chemistry · doi:10.1039/c5ob00169b · Cited by 166 · see citing works

Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl]thiazolidine): A highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

Yoshida, T., Akahoshi, F., Sakashita, H., Kitajima, H., Nakamura, M., Sonda, S., Takeuchi, M., Tanaka, Y., Ueda, N., Sekiguchi, S., et al. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.08.012 · Cited by 156 · see citing works

Homoharringtonine/Omacetaxine Mepesuccinate: The Long and Winding Road to Food and Drug Administration Approval

Kantarjian, H. M., O'Brien, S. M., & Cortes, J. E. (2013) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2013.03.017 · Cited by 140 · see citing works

Development of a Concise Synthesis of (+)-Ingenol

McKerrall, S. J., Jørgensen, L., Kuttruff, C. A., et al. (2014) · Journal of the American Chemical Society · doi:10.1021/ja501881p · Cited by 139 · see citing works

Dark chemical matter as a promising starting point for drug lead discovery

Wassermann, A. M., Lounkine, E., Hoepfner, D., Goff, G. L., King, F. J., Studer, C., Peltier, J. M., Grippo, M. L., Prindle, V. C., Tao, J., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1936 · Cited by 135 · see citing works

Discovery of Ipragliflozin (ASP1941): A novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus

Imamura, M., Nakanishi, K., Suzuki, T., et al. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.03.051 · Cited by 134 · see citing works

Prospecting for new bacterial metabolites: a glossary of approaches for inducing, activating and upregulating the biosynthesis of bacterial cryptic or silent natural products

Zarins-Tutt, J. S., Barberi, T. T., Gao, H. C., Mearns-Spragg, A., Zhang, L., Newman, D. J., & Goss, R. J. M. (2015) · Natural Product Reports · doi:10.1039/c5np00111k · Cited by 134 · see citing works

Stoffwechselprodukte von Mikroorganismen. 57. Mitteilung. Boromycin

Hütter, R., Keller‐Schien, W., Knüsel, F., et al. (1967) · Helvetica Chimica Acta · doi:10.1002/hlca.19670500612 · Cited by 128 · see citing works

A stereocontrolled synthesis of hydroxyethylene dipeptide isosteres using novel, chiral aminoalkyl epoxides and .gamma.-(aminoalkyl)-.gamma.-lactones

Evans, B., Rittle, K. E., Homnick, C. F., et al. (1985) · The Journal of Organic Chemistry · doi:10.1021/jo00223a037 · Cited by 118 · see citing works

Synthetic approaches to the 2011 new drugs

Ding, H. X., Liu, K. K. ‐., Sakya, S. M., Flick, A. C., & O’Donnell, C. J. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.02.061 · Cited by 113 · see citing works

Ataluren: First Global Approval

Ryan, N. J. (2014) · Drugs · doi:10.1007/s40265-014-0287-4 · Cited by 111 · see citing works

Developing natural product drugs: Supply problems and how they have been overcome

Newman, D. J. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.12.002 · Cited by 111 · see citing works

New tools for reconstruction and heterologous expression of natural product biosynthetic gene clusters

Luo, Y., Enghiad, B., & Zhao, H. (2015) · Natural Product Reports · doi:10.1039/c5np00085h · Cited by 105 · see citing works

Identification and analysis of the bacterial endosymbiont specialized for production of the chemotherapeutic natural product ET ‐743

Schofield, M. M., Jain, S., Porat, D., et al. (2015) · Environmental Microbiology · doi:10.1111/1462-2920.12908 · Cited by 103 · see citing works

Flavonolignans from Aspergillus iizukae, a Fungal Endophyte of Milk Thistle (Silybum marianum)

El‐Elimat, T., Raja, H. A., Graf, T. N., et al. (2014) · Journal of Natural Products · doi:10.1021/np400955q · Cited by 101 · see citing works

Glucagon-Like Peptide 1 Receptor Agonist ZP10A Increases Insulin mRNA Expression and Prevents Diabetic Progression in db/db Mice

Thorkildsen, C., Neve, S., Larsen, B. D., Meier, E., & Petersen, J. S. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.051987 · Cited by 99 · see citing works

Tofogliflozin: First Global Approval

Poole, R. M., & Prossler, J. E. (2014) · Drugs · doi:10.1007/s40265-014-0229-1 · Cited by 99 · see citing works

The development of immunoconjugates for targeted cancer therapy

Smaglo, B. G., Aldeghaither, D. S., & Weiner, L. M. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.159 · Cited by 98 · see citing works

Natural product-like chemical space: search for chemical dissectors of macromolecular interactions

Reayi, A., & Arya, P. (2005) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2005.04.007 · Cited by 95 · see citing works

Natural Products in Medicine: Transformational Outcome of Synthetic Chemistry

Szychowski, J., Truchon, J., & Bennani, Y. L. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500941m · Cited by 94 · see citing works

Discovery and pharmacological characterization of N-[2-({2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl}amino)-2-methylpropyl]-2-methylpyrazolo[1,5-a]pyrimidine-6-carboxamide hydrochloride (anagliptin hydrochloride salt) as a potent and selective DPP-IV inhibitor

Kato, N., Oka, M., Murase, T., Yoshida, M., Sakairi, M., Yamashita, S., Yasuda, Y., Yoshikawa, A., Hayashi, Y., Makino, M., et al. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.09.043 · Cited by 91 · see citing works

Boromycin, an Anti-HIV Antibiotic

Kohno, J., Kawahata, T., Otake, T., et al. (1996) · Bioscience Biotechnology and Biochemistry · doi:10.1271/bbb.60.1036 · Cited by 90 · see citing works

Synthetic approaches to the 2013 new drugs

Ding, H. X., Leverett, C. A., Kyne, R. E., Liu, K. K. ‐., Fink, S. J., Flick, A. C., & O’Donnell, C. J. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.02.056 · Cited by 85 · see citing works

Synthetic approaches to the 2009 new drugs

Liu, K. K. ‐., Sakya, S. M., O’Donnell, C. J., et al. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.12.038 · Cited by 84 · see citing works

Endophytes Are Hidden Producers of Maytansine in Putterlickia Roots

Kusari, S., Lamshöft, M., Kusari, P., Gottfried, S., Zühlke, S., Louven, K., Hentschel, U., Kayser, O., & Spiteller, M. (2014) · Journal of Natural Products · doi:10.1021/np500219a · Cited by 80 · see citing works

Small molecule modulators of protein-protein interactions: selected case studies

Aeluri, M., Chamakuri, S., Dasari, B., Guduru, S. K. R., Jimmidi, R., Jogula, S., & Arya, P. (2014) · Chemical Reviews · doi:10.1021/cr4004049 · Cited by 79 · see citing works

Analysis of Physicochemical Properties for Drugs of Natural Origin

Camp, D., Garavelas, A., & Campitelli, M. R. (2015) · Journal of Natural Products · doi:10.1021/acs.jnatprod.5b00255 · Cited by 77 · see citing works

Academia–Industry Symbiosis in Organic Chemistry

Michaudel, Q., Ishihara, Y., & Baran, P. S. (2015) · Accounts of Chemical Research · doi:10.1021/ar500424a · Cited by 76 · see citing works

Macrocycles in Drug Discovery

Levin, J. I. (2014) · Royal Society of Chemistry eBooks · doi:10.1039/9781782623113 · Cited by 76 · see citing works

Direct Renin Inhibitors as a New Therapy for Hypertension

Webb, R. L., Schiering, N., Sedrani, R. C., & Maibaum, J. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901885s · Cited by 74 · see citing works

Natural products as leads to antitumor drugs

Newman, D. J., & Giddings, L. (2013) · Phytochemistry Reviews · doi:10.1007/s11101-013-9292-6 · Cited by 73 · see citing works

Stereocontrolled Solid‐Phase Synthesis of a 90‐Membered Library of Indoline‐Alkaloid‐like Polycycles from an Enantioenriched Aminoindoline Scaffold

Gan, Z., Reddy, P. T., Quevillon, S., et al. (2005) · Angewandte Chemie International Edition · doi:10.1002/anie.200462298 · Cited by 72 · see citing works

Synthetic approaches to the 2010 new drugs

Liu, K. K. ‐., Sakya, S. M., O’Donnell, C. J., Flick, A. C., & Ding, H. X. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.12.049 · Cited by 69 · see citing works

Dereplication, sequencing and identification of peptidic natural products: from genome mining to peptidogenomics to spectral networks

Mohimani, H., & Pevzner, P. A. (2015) · Natural Product Reports · doi:10.1039/c5np00050e · Cited by 68 · see citing works

Structure Diversification of Vancomycin through Peptide-Catalyzed, Site-Selective Lipidation: A Catalysis-Based Approach To Combat Glycopeptide-Resistant Pathogens

Yoganathan, S., & Miller, S. J. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501872s · Cited by 65 · see citing works

Implications of endophyte-plant crosstalk in light of quorum responses for plant biotechnology

Kusari, P., Kusari, S., Spiteller, M., et al. (2015) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-015-6660-8 · Cited by 61 · see citing works

Opportunities for Synthetic Biology in Antibiotics: Expanding Glycopeptide Chemical Diversity

Thaker, M., & Wright, G. D. (2012) · ACS Synthetic Biology · doi:10.1021/sb300092n · Cited by 57 · see citing works

Synthesis and evaluation of 6-methylene-bridged uracil derivatives. Part 2: Optimization of inhibitors of human thymidine phosphorylase and their selectivity with uridine phosphorylase

Yano, S., Kazuno, H., Sato, T., et al. (2004) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2004.04.046 · Cited by 54 · see citing works

Synthetic approaches to the 2012 new drugs

Ding, H. X., Leverett, C. A., Kyne, R. E., Liu, K. K. ‐., Sakya, S. M., Flick, A. C., & O’Donnell, C. J. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.02.017 · Cited by 51 · see citing works

The year's new drugs & biologics - 2009

Graul, A. I., Sorbera, L. A., Pina, P., et al. (2010) · Drug News & Perspectives · doi:10.1358/dnp.2010.23.1.1440373 · Cited by 48 · see citing works

Biosynthetic medicinal chemistry of natural product drugs

Koehn, F. E. (2012) · MedChemComm · doi:10.1039/c2md00316c · Cited by 44 · see citing works

To Market, To Market—2004

Hegde, S. G., & Schmidt, M. A. (2005) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(05)40029-9 · Cited by 44 · see citing works

Dual Inhibitors for Aspartic Proteases HIV-1 PR and Renin: Advancements in AIDS–Hypertension–Diabetes Linkage via Molecular Dynamics, Inhibition Assays, and Binding Free Energy Calculations

Tzoupis, H., Leonis, G., Megariotis, G., Supuran, C. T., Mavromoustakos, T., & Παπαδόπουλος, Μ. Γ. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300180r · Cited by 43 · see citing works

Hexacyclopeptides secreted by an endophytic fungus Fusarium solani N06 act as crosstalk molecules in Narcissus tazetta

Wang, W.-X., Kusari, S., Sezgin, S., Lamshöft, M., Kusari, P., Kayser, O., & Spiteller, M. (2015) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-015-6653-7 · Cited by 43 · see citing works

Spongosine Production by a Vibrio harveyi Strain Associated with the Sponge Tectitethya crypta

Bertin, M. J., Schwartz, S. L., Lee, J., Korobeynikov, A., Dorrestein, P. C., Gerwick, L. G., & Gerwick, W. H. (2015) · Journal of Natural Products · doi:10.1021/np5009762 · Cited by 42 · see citing works

Design and synthesis of HIV protease inhibitors. Variations of the carboxyterminus of the HIV protease inhibitor L-682,679

DeSolms, S. J., Giuliani, E. A., Guare, J. P., et al. (1991) · Journal of Medicinal Chemistry · doi:10.1021/jm00113a025 · Cited by 41 · see citing works

Empagliflozin, an SGLT2 Inhibitor for the Treatment of Type 2 Diabetes Mellitus

White, J. R. (2015) · Annals of Pharmacotherapy · doi:10.1177/1060028015573564 · Cited by 37 · see citing works

The European Medicines Agency Review of Pixantrone for the Treatment of Adult Patients With Multiply Relapsed or Refractory Aggressive Non-Hodgkin's B-Cell Lymphomas: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use

Péan, E., Flores, B., Hudson, I., et al. (2013) · The Oncologist · doi:10.1634/theoncologist.2013-0020 · Cited by 36 · see citing works

Brentuximab vedotin: delivering an antimitotic drug to activated lymphoma cells

Ansell, S. M. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.542147 · Cited by 36 · see citing works

Learning from PAINful lessons

Erlanson, D. A. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00294 · Cited by 33 · see citing works

To Market, To Market—2011

Bronson, J. J., Dhar, T. G. M., Ewing, W. R., & Lönberg, N. (2012) · Annual reports in medicinal chemistry · doi:10.1016/b978-0-12-396492-2.00031-x · Cited by 33 · see citing works

Chapter 28. To market, to market — 2000

Gaudillière, B., Bernardelli, P., & Berna, P. P. (2001) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(01)36068-2 · Cited by 28 · see citing works

Chapter 26. To market, to market - 2001

Bernardelli, P., Gaudillière, B., & Vergne, F. (2002) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(02)37027-1 · Cited by 26 · see citing works

Recognition of the role of Natural Products as drugs to treat neglected tropical diseases by the 2015 Nobel prize in physiology or medicine

McKerrow, J. H. (2015) · Natural Product Reports · doi:10.1039/c5np90043c · Cited by 26 · see citing works

To Market, To Market – 2005

Hegde, S. G., & Schmidt, M. A. (2006) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(06)41030-7 · Cited by 24 · see citing works

The Chemistry-Biology-Medicine Continuum and the Drug Discovery and Development Process in Academia

Nicolaou, K. C. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.07.020 · Cited by 24 · see citing works

Bioactive Compounds from Terrestrial Extremophiles

Giddings, L., & Newman, D. J. (2014) · SpringerBriefs in microbiology · doi:10.1007/978-3-319-13260-0_1 · Cited by 23 · see citing works

Chapter 33. To market, to market - 2002

Boyer-Joubert, C., Lorthiois, E., & Moreau, F. (2003) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(03)38034-0 · Cited by 23 · see citing works

The expanding role of immunopharmacology: IUPHAR Review 16

Tiligada, E., Ishii, M., Riccardi, C., Spedding, M., Simon, H., Teixeira, M. M., Cuervo, M. L. C., Holgate, S. T., & Levi‐Schaffer, F. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13219 · Cited by 23 · see citing works

Natural Products as Pharmaceuticals and Sources for Lead Structures**Note: This chapter reflects the opinions of the authors, not necessarily those of the US Government

Newman, D. J., Cragg, G. M. L., & Kingston, D. G. I. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-417205-0.00005-5 · Cited by 23 · see citing works

To Market, To Market—2010

Bronson, J. J., Dhar, T. G. M., Ewing, W. R., & Lönberg, N. (2011) · Annual reports in medicinal chemistry · doi:10.1016/b978-0-12-386009-5.00002-3 · Cited by 22 · see citing works

2012 In review - Part I: The year's new drugs and biologics

Graul, A., Lupone, B., Cruces, E., et al. (2013) · Drugs of today · doi:10.1358/dot.2013.49.1.1933991 · Cited by 22 · see citing works

Canagliflozin

Chao, E. C. (2011) · Drugs of the Future · doi:10.1358/dof.2011.036.05.1590789 · Cited by 22 · see citing works

Bioactive Compounds from Marine Extremophiles

Giddings, L., & Newman, D. J. (2015) · SpringerBriefs in microbiology · doi:10.1007/978-3-319-14361-3 · Cited by 21 · see citing works

To Market, To Market — 2007

Hegde, S. G., & Schmidt, M. A. (2008) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(08)00025-0 · Cited by 21 · see citing works

The Year's New Drugs & Biologics, 2013: Part I

Graul, A., Cruces, E., & Stringer, M. (2014) · Drugs of today · doi:10.1358/dot.2014.50.1.2116673 · Cited by 21 · see citing works

Section VII. Trends and perspectives

Gaudillière, B., & Berna, P. P. (2000) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(00)35031-x · Cited by 20 · see citing works

“Pruning of biomolecules and natural products (PBNP)”: an innovative paradigm in drug discovery

Bathula, S. R., Murthy, A. S., Mainkar, P. S., & Chandrasekhar, S. (2015) · Organic & Biomolecular Chemistry · doi:10.1039/c5ob00403a · Cited by 19 · see citing works

Bioactive Macrocycles from Nature

Newman, D. J., & Cragg, G. M. L. (2014) · Royal Society of Chemistry eBooks · doi:10.1039/9781782623113-00001 · Cited by 19 · see citing works

To Market, To Market—2012

Bronson, J. J., Black, A., Dhar, T. G. M., Ellsworth, B. A., & Merritt, J. R. (2013) · Annual reports in medicinal chemistry · doi:10.1016/b978-0-12-417150-3.00028-4 · Cited by 18 · see citing works

Chapter 31. To Market, To Market - 1990

Strupczewski, J. D., Ellis, D. B., & Allen, R. C. (1991) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(08)61218-x · Cited by 18 · see citing works

Chapter 34. To Market, To Market – 1992

Strupczewski, J. D., & Ellis, D. B. (1993) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(08)60904-5 · Cited by 17 · see citing works

Chapter 31. To Market, To Market - 1996

Galatsis, P. (1997) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(08)61489-x · Cited by 17 · see citing works

The year's new drugs & biologics, 2010

Graul, A., & Cruces, E. (2011) · Drugs of today · doi:10.1358/dot.2011.47.1.1587820 · Cited by 17 · see citing works

Chapter 31. To Market, To Market - 1998

Gaudillière, B. (1999) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(08)60593-x · Cited by 16 · see citing works

Bioactive Compounds from Marine Extremophiles

Giddings, L., & Newman, D. J. (2015) · SpringerBriefs in microbiology · doi:10.1007/978-3-319-14361-3_1 · Cited by 16 · see citing works

Chapter 33. To Market, To Market - 1991

Strupczewski, J. D., & Ellis, D. B. (1992) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(08)60431-5 · Cited by 15 · see citing works

Chapter 32 To Market, To Market – 2006

Hegde, S. G., & Schmidt, M. A. (2007) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(07)42032-2 · Cited by 15 · see citing works

How dark is HTS dark matter?

Macarrón, R. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1937 · Cited by 15 · see citing works

Chapter 28 To Market, To Market — 2008

Hegde, S. G., & Schmidt, M. A. (2009) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(09)04428-5 · Cited by 14 · see citing works

(−)‐Tarchonanthuslactone: Design of New Analogues, Evaluation of their Antiproliferative Activity on Cancer Cell Lines, and Preliminary Mechanistic Studies

Novaes, L. F. T., Avila, C. M., Pelizzaro‐Rocha, K. J., et al. (2015) · ChemMedChem · doi:10.1002/cmdc.201500246 · Cited by 14 · see citing works

The year's new drugs & biologics, 2013: Part II

Graul, A. I., Navarro, D., Dulsat, C., et al. (2014) · Drugs of today · doi:10.1358/dot.2014.50.2.2122810 · Cited by 14 · see citing works

Chapter 31. To Market, To Market -1988

Ong, H. H., & Allen, R. C. (1989) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(08)60553-9 · Cited by 14 · see citing works

The year's new drugs and biologics, 2014: Part I

Graul, A., Cruces, E., & Stringer, M. D. (2015) · Drugs of today · doi:10.1358/dot.2015.51.1.2279964 · Cited by 14 · see citing works

To Market, To Market - 1997

Galatsis, P. (1998) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(08)61097-0 · Cited by 14 · see citing works

To Market, To Market—2013

Bronson, J. J., Black, A., Dhar, T. G. M., Ellsworth, B. A., & Merritt, J. R. (2014) · Annual reports in medicinal chemistry · doi:10.1016/b978-0-12-800167-7.00027-4 · Cited by 13 · see citing works

Conformational Properties and Energetic Analysis of Aliskiren in Solution and Receptor Site

Politi, A., Leonis, G., Tzoupis, H., Ntountaniotis, D., Παπαδόπουλος, Μ. Γ., Grdadolnik, S. G., & Mavromoustakos, T. (2011) · Molecular Informatics · doi:10.1002/minf.201100077 · Cited by 13 · see citing works

The Year's New Drugs & Biologics, 2011

Graul, A., Cruces, E., Dulsat, C., et al. (2012) · Drugs of today · doi:10.1358/dot.2012.48.1.1769676 · Cited by 13 · see citing works

The year's new drugs & biologics - 2008

Graul, A. I., Revel, L., Barrionuevo, M., et al. (2009) · Drug News & Perspectives · doi:10.1358/dnp.2009.22.1.1303754 · Cited by 12 · see citing works

Academic–Industrial Partnerships in Drug Discovery and Development

Nicolaou, K. C. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201402816 · Cited by 12 · see citing works

The European Medicines Agency approval of 5-aminolaevulinic acid (Ameluz) for the treatment of actinic keratosis of mild to moderate intensity on the face and scalp: Summary of the scientific assessment of the Committee for Medicinal Products for Human Use

Tzogani, K., Straube, M., Hoppe, U., et al. (2013) · Journal of Dermatological Treatment · doi:10.3109/09546634.2013.789474 · Cited by 12 · see citing works

Chapter 33. To Market, To Market – 1987

Ong, H. H., & Allen, R. C. (1988) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(08)60861-1 · Cited by 11 · see citing works

Chapter 31. To Market, To Market - 1983

Allen, R. C. (1984) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(08)60707-1 · Cited by 9 · see citing works

Chapter 33. To Market, To Market - 1989

Ong, H. H., & Allen, R. C. (1990) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(08)61609-7 · Cited by 8 · see citing works

To Market, To Market--2014

Bronson, J. J., Peese, K. M., Black, A., et al. (2015) · Medicinal chemistry reviews · doi:10.29200/acsmedchemrev-v50.ch19 · Cited by 8 · see citing works

BI-1356

Wang, Y., Serradell, N., Rosa, E., et al. (2008) · Drugs of the Future · doi:10.1358/dof.2008.033.06.1215244 · Cited by 8 · see citing works

Trastuzumab emtansine, tumor-activated prodrug (TAP) immunoconjungate, oncolytic

Kümler, I., Mortensen, C. E., & Nielsen, D. (2011) · Drugs of the Future · doi:10.1358/dof.2011.036.11.1711891 · Cited by 7 · see citing works

Abiraterone acetate

Shah, S., & Ryan, C. J. (2009) · Drugs of the Future · doi:10.1358/dof.2009.034.11.1441113 · Cited by 7 · see citing works

Chapter 31. To Market, To Market - 1985

Allen, R. C. (1986) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(08)61141-0 · Cited by 6 · see citing works

Dapagliflozin

Cole, P., Vicente, M., & Castaner, R. (2008) · Drugs of the Future · doi:10.1358/dof.2008.033.09.1251351 · Cited by 6 · see citing works

Biopharmaceutical Drugs from Natural Sources

Newman, D. J., Cragg, G. M. L., & O’Keefe, B. R. (2005) · doi:10.1002/9783527620982.ch19 · Cited by 5 · see citing works

Discovery and development of natural compounds into medicinal products

Camp, D. (2013) · Drugs of the Future · doi:10.1358/dof.2013.038.04.1940442 · Cited by 5 · see citing works

Chapter 31 To Market, To Market - 1986

Allen, R. C. (1987) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(08)61179-3 · Cited by 5 · see citing works

Luseogliflozin

Tiwari, A. (2012) · Drugs of the Future · doi:10.1358/dof.2012.037.09.1848191 · Cited by 3 · see citing works

Techniques for extraction and isolation of natural products: A comprehensive review

Zhang, Q.-W., Lin, L.-G., & Ye, W.-C. (2018) · Chinese Medicine · doi:10.1186/s13020-018-0177-x · Cited by 2,321 · see citing works

Opportunities and challenges in phenotypic drug discovery: an industry perspective

Moffat, J. G., Vincent, F., Lee, J. A., Eder, J., & Prunotto, M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.111 · Cited by 939 · see citing works

Colorectal Cancer: A Review of Carcinogenesis, Global Epidemiology, Current Challenges, Risk Factors, Preventive and Treatment Strategies

Hossain, M. S., Karuniawati, H., Jairoun, A. A., Urbi, Z., Ooi, D. J., John, A., Lim, Y. C., Kibria, K. M. K., Mohiuddin, A. K. M., Ming, L. C., et al. (2022) · Cancers · doi:10.3390/cancers14071732 · Cited by 920 · see citing works

Marine Natural Products: A Source of Novel Anticancer Drugs

Khalifa, S. A. M., Elias, N., Farag, M. A., Chen, L., Saeed, A., Hegazy, M.-E. F., Moustafa, M. S., Abd El-Wahed, A., Al-Mousawi, S. M., Musharraf, S. G., et al. (2019) · Marine Drugs · doi:10.3390/md17090491 · Cited by 555 · see citing works

A review of large language models and autonomous agents in chemistry

Ramos, M. C., Collison, C. J., & White, A. D. (2025) · Chemical Science · doi:10.1039/d4sc03921a · Cited by 274 · see citing works

Cyanobacteria: Promising biocatalysts for sustainable chemical production

Knoot, C. J., Ungerer, J., Wangikar, P. P., & Pakrasi, H. B. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.r117.815886 · Cited by 225 · see citing works

Isothiocyanates: An Overview of Their Antimicrobial Activity against Human Infections

Romeo, L., Iori, R., Rollin, P., Bramanti, P., & Mazzon, E. (2018) · Molecules · doi:10.3390/molecules23030624 · Cited by 230 · see citing works

Small molecules regulating reactive oxygen species homeostasis for cancer therapy

Zhang, J., Duan, D., Song, Z., Liu, T., Hou, Y., & Fang, J. (2021) · Medicinal Research Reviews · doi:10.1002/med.21734 · Cited by 184 · see citing works

Chemoproteomics-enabled discovery of covalent RNF114-based degraders that mimic natural product function

Luo, M., Spradlin, J. N., Boike, L., Tong, B., Brittain, S. M., McKenna, J. M., Tallarico, J. A., Schirle, M., Maimone, T. J., & Nomura, D. K. (2021) · Cell Chemical Biology · doi:10.1016/j.chembiol.2021.01.005 · Cited by 186 · see citing works

Current Status and Future Prospects of Marine Natural Products (MNPs) as Antimicrobials

Choudhary, A., Naughton, L., Montánchez, I., Dobson, A., & Rai, D. (2017) · Marine Drugs · doi:10.3390/md15090272 · Cited by 138 · see citing works

Cannabinoids Block Cellular Entry of SARS-CoV-2 and the Emerging Variants

van Breemen, R. B., Muchiri, R. N., Bates, T. A., Weinstein, J. B., Leier, H. C., Farley, S., & Tafesse, F. G. (2022) · Journal of Natural Products · doi:10.1021/acs.jnatprod.1c00946 · Cited by 135 · see citing works

Extending the small-molecule similarity principle to all levels of biology with the Chemical Checker

Duran-Frigola, M., Pauls, E., Guitart-Pla, O., Bertoni, M., Alcalde, V., Amat, D., Juan-Blanco, T., & Aloy, P. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0502-7 · Cited by 126 · see citing works

Natural Products as a Potential Modulator of Microglial Polarization in Neurodegenerative Diseases

Jin, X., Liu, M.-Y., Zhang, D.-F., Zhong, X., Du, K., Qian, P., Gao, H., & Wei, M.-J. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104253 · Cited by 109 · see citing works

Ipomoeassin F Binds Sec61α to Inhibit Protein Translocation

Zong, G., Hu, Z., O’Keefe, S., Tranter, D., Iannotti, M. J., Baron, L., Hall, B., Corfield, K., Paatero, A. O., Henderson, M. J., et al. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.8b13506 · Cited by 93 · see citing works

A Review on Annona muricata and Its Anticancer Activity

Ilango, S., Sahoo, D. K., Paital, B., Kathirvel, K., Gabriel, J. I., Subramaniam, K., Jayachandran, P., Dash, R. K., Hati, A. K., Behera, T. R., et al. (2022) · Cancers · doi:10.3390/cancers14184539 · Cited by 91 · see citing works

The natural product eugenol is an inhibitor of the ebola virus in vitro

Lane, T., Anantpadma, M., Freundlich, J. S., Davey, R. A., Madrid, P. B., & Ekins, S. (2019) · Pharmaceutical Research · doi:10.1007/s11095-019-2629-0 · Cited by 88 · see citing works

Antiviral Cyanometabolites—A Review

Mazur-Marzec, H., Cegłowska, M., Konkel, R., & Pyrć, K. (2021) · Biomolecules · doi:10.3390/biom11030474 · Cited by 64 · see citing works

Design of Gallinamide A Analogs as Potent Inhibitors of the Cysteine Proteases Human Cathepsin L and <i>Trypanosoma cruzi</i> Cruzain

Boudreau, P. D., Miller, B. W., McCall, L.-I., Almaliti, J., Reher, R., Hirata, K., Le, T., Siqueira-Neto, J. L., Hook, V., & Gerwick, W. H. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00294 · Cited by 57 · see citing works

Discovery of human cell selective effector molecules using single cell multiplexed activity metabolomics

Earl, D. C., Ferrell, P. B., Leelatian, N., Froese, J. T., Reisman, B. J., Irish, J. M., & Bachmann, B. O. (2018) · Nature Communications · doi:10.1038/s41467-017-02470-8 · Cited by 48 · see citing works

Essential Medicinal Chemistry of Essential Medicines

Serafini, M., Cargnin, S., Massarotti, A., Pirali, T., & Genazzani, A. A. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00415 · Cited by 46 · see citing works

Kalopanaxsaponin A induces reactive oxygen species mediated mitochondrial dysfunction and cell membrane destruction in Candida albicans

Li, Y., Shan, M., Zhu, Y., Yao, H., Li, H., Gu, B., & Zhu, Z. (2020) · PLOS ONE · doi:10.1371/journal.pone.0243066 · Cited by 35 · see citing works

Brazilian Red Propolis Is as Effective as Amoxicillin in Controlling Red-Complex of Multispecies Subgingival Mature Biofilm In Vitro

de Figueiredo, K. A., da Silva, H. D. P., Miranda, S. L. F., Gonçalves, F. J. D. S., de Sousa, A. P., de Figueiredo, L. C., Feres, M., & Bueno-Silva, B. (2020) · Antibiotics · doi:10.3390/antibiotics9080432 · Cited by 32 · see citing works

Chiloscyphenol A derived from Chinese liverworts exerts fungicidal action by eliciting both mitochondrial dysfunction and plasma membrane destruction

Zheng, S., Chang, W., Zhang, M., Shi, H., & Lou, H. (2018) · Scientific Reports · doi:10.1038/s41598-017-18717-9 · Cited by 23 · see citing works

Beyond Antioxidant Effects: Nature-Based Templates Unveil New Strategies for Neurodegenerative Diseases

Bacci, A., Runfola, M., Sestito, S., & Rapposelli, S. (2021) · Antioxidants · doi:10.3390/antiox10030367 · Cited by 23 · see citing works

Argentatin B derivatives induce cell cycle arrest and DNA damage in human colon cancer cells through p73/p53 regulation

Romero-Benavides, J. C., Bailon-Moscoso, N., Parra-Delgado, H., Ramirez, M. I., Villacis, J., Cabrera, H., Gonzalez-Arevalo, G., Cueva, R., Zentella-Dehesa, A., Ratovitski, E. A., et al. (2018) · Medicinal Chemistry Research · doi:10.1007/s00044-017-2106-4 · Cited by 17 · see citing works

An immunogenic cell injury module for the single-cell multiplexed activity metabolomics platform to identify promising anti-cancer natural products

Balsamo, J. A., Penton, K. E., Zhao, Z., Hayes, M. J., Lima, S. M., Irish, J. M., & Bachmann, B. O. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102300 · Cited by 12 · see citing works

Spirulina and Herbal Combination on Metabolic Alterations of Cardiovascular Diseases (CVDs)

Pandey, R., & Singh, S. (2022) · International Journal of Research and Review · doi:10.52403/ijrr.20220334 · Cited by 6 · see citing works

ИСПОЛЬЗОВAНИЕ ПОТЕНЦИAЛA СОЦИAЛЬНЫХ ПAРТНЕРОВ В ПОДГОТОВКЕ БУДУЩИХ ПЕДAГОГОВ

Атабекова, Б. Б. (2024) · Habaršy. Pedagogika ġylymdary seriâsy · doi:10.51889/2959-5762.2023.80.4.019

DETERMINING QUALITY REQUIREMENTS AT THE UNIVERSITIES TO IMPROVE THE QUALITY OF EDUCATION

Mustafa, N. H., Kelesbayev, D., & Alibekova, Z. D. (2018) · The Journal of Economic Research & Business Administration · doi:10.26577/be-2018-2-2141

Susquehanna Chorale Spring Concert "Roots and Wings"

Hawkins, D. (2017)

Genentech taps Affimed’s antibodies

Cross, R. (2018) · C&EN Global Enterprise · doi:10.1021/cen-09635-buscon15

KOMPLIKASI REGIONAL ANESTESI PADA PEDIATRIK

Sari, D. (2023) · Jurnal Komplikasi Anestesi · doi:10.22146/jka.v5i1.7322